Criterion 3 for abnormal Q waves (>3mm depth and/or >0.04s duration in ≥2 leads except aVR) was present in 27.6% of preclinical HCM carriers versus 5.4% of non-carriers (P<0.01).
Observational (n=148)
Absolute Event Rate: 27.6% vs 5.4%
p-value: p=<0.01
AIMS: There are currently no established diagnostic criteria for the identification of abnormal Q waves in patients with hypertrophic cardiomyopathy (HCM), resulting in various definitions being applied in each previous study. The aim of this study was to determine the most accurate diagnostic definition of abnormal Q waves for HCM based on a molecular genetic diagnosis, and also to apply abnormal Q waves to the identification of preclinical carriers. METHODS AND RESULTS: We applied three different criteria used in previous reports for abnormal Q waves in 148 genotyped subjects. Of the three criteria, Criterion 3 (Q wave >3mm in depth and/or >0.04s in duration in at least two leads except aVR) showed the highest sensitivity (50% in the young, 29% in adults) while retaining a high specificity (90% in the young, 97% in adults), resulting in the highest accuracy (69% in the young, 52% in adults). Using Criterion 3, abnormal Q waves were present 27.6% of preclinical carriers, and in 5.4% of non-carriers (P<0.01). CONCLUSIONS: These findings suggest that Criterion 3 may be the most accurate diagnostic definition for HCM. Understanding the diagnostic value of abnormal Q waves may be useful in screening preclinical carriers of HCM.
Tetsuo Konno (Sun,) conducted a observational in Hypertrophic cardiomyopathy (n=148). Criterion 3 for abnormal Q waves (depth >3mm and/or duration >0.04s in ≥2 leads except aVR) vs. Non-carriers was evaluated on Presence of abnormal Q waves (p=<0.01). Criterion 3 for abnormal Q waves (>3mm depth and/or >0.04s duration in ≥2 leads except aVR) was present in 27.6% of preclinical HCM carriers versus 5.4% of non-carriers (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: